(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Progress in Repurchasing A-Shares
Filed with SSE · Stock code 600276 · · 2 pages · Chinese
Summary by 6ix AI
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced progress on its A-share repurchase plan. The repurchase is part of a strategy to implement an employee stock ownership plan and maintain shareholder value. The announcement includes details on the repurchase price range and total amount spent so far.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Jiangsu Hengrui Pharmaceuticals Co., Ltd. on 6ix
Story so far
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Receipt of the Drug Clinical Trial Approval Notice
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Obtaining Drug Registration Approval
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Resolutions of the 5th Meeting of the 10th Board of Directors
Earlier from Jiangsu Hengrui Pharmaceuticals
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Acceptance of Application for Drug Marketing Authorization and Inclusion in the Priority Review Program
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Receipt of the Drug Clinical Trial Approval Notice
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Report for Q3 2026
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Resolutions of the 5th Meeting of the 10th Board of Directors
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Obtaining Drug Registration Approval
Later from Jiangsu Hengrui Pharmaceuticals
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Resolutions of the 6th Meeting of the 10th Board of Directors
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on FDA Acceptance of the Resubmitted Biologics License Application for Camrelizumab for Injection
- Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Satisfaction of Unlocking Conditions for Certain Shares under the 2025 A-Share Employee Stock Ownership Plan and Expiration of the 1st Lock-up Period
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Completion of Unlocking of the 1st Lock-up Period of the 2025 A-Share Employee Stock Ownership Plan
Follow Jiangsu Hengrui Pharmaceuticals into a list and get an email when it puts out news.
Follow Jiangsu Hengrui Pharmaceuticals